July Investor Update
Dear investors,
I am pleased to provide you with an update on our progress over the last month.Overall, the token listing faced a rocky start, but we have made significant strides in delivering “real-world” data collection programs that will drive long-term demand for the token.
Here are the recent developments:
1. DexListing on Quickswap:
The IMM token was listed on July 22. However, there was a substantial sell-down from two wallets that were not in any way connected to the Immunify team or staff.
The 2 main trading Contracts:
IMM Token: 0xcc58986a64ad55ae543d18691958c94b565a610a Quickswap Pair: 0x6fe49eb1be9ac845b429f1de7bd8866ef87fd489
Liquidity:
We are gradually building our single-sided staking on Quickswap with a current offering of 350% APR, which will reduce to sustainable levels as volume increases.
However, we acknowledge liquidity remains a challenge, and as part of ongoing efforts to address this issue, we are actively working on delivering a two-sided staking solution. This solution aims to attract additional interest and help ease liquidity concerns.
2. Zambia:
We have successfully completed the vaccination study and obtained national regulatory approval in conjunction with government clinics.
The study write-up has been completed by the principal investigator, with input from the statistician.The first version of the malaria module has been completed, reviewed, and necessary changes made. Refer report enclosed Zambia Study
Our next step is to meet with the minister to discuss the malaria prevention project, which has significant potential for commercialisation and generating real token demand.
3. Australian Government Co-Funding:
The Australian Government’s Department of Industry, Science, and Resources has reviewed and approved our submission for funding of our research in Kenya and Zambia.
This approval represents a significant milestone for Immunify Life, as it qualifies our project as a core research and development activity, making it eligible for the rebate scheme.
The approved grant will provide essential additional funding to support our vital research work in Kenya and Zambia.
4. MOU with Ellipsis:
We have established a memorandum of understanding with Ellipsis to conduct a study on HIV and other diseases. The study and its results will be instrumental in proving our business case and raising our profile with crypto investors, business partners, and data purchasers.
5. Nigeria Market Development with Iflux Blue Loop:
The developers of our patient app, IFLX/Blue Loop, have a substantial customer base in Nigeria, boasting 25,000 active users of their crypto-fiat gateway app.
In closing, we extend our sincere gratitude for your continued support and patience. As we get closer to commercialisation, excitement is building among our team, and we remain committed to realising our shared vision.
Thank you for being part of our journey.
Sincerely,
Guy.
